Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (24)

2022

  1. Contribution of the Elastic Component and Venous Wall Arterialization in Patients with Venous Reflux

    Journal of Personalized Medicine, Vol. 12, Núm. 2

  2. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

  3. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

2020

  1. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

2018

  1. Asymmetric cellulose triacetate is a safe and effective alternative for online haemodiafiltration

    Nefrologia, Vol. 38, Núm. 3, pp. 315-320

2017

  1. Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease

    Biomarkers, Vol. 22, Núm. 2, pp. 133-144

  2. Markers of endothelial damage in patients with chronic kidney disease on hemodialysis

    American Journal of Physiology - Renal Physiology, Vol. 312, Núm. 4, pp. F673-F681

2016

  1. Guideline for dialysate quality of Spanish Society of Nephrology (second edition, 2015)

    Nefrologia, Vol. 36, Núm. 3, pp. e1-e52

  2. Guía de gestión de calidad del líquido de diálisis (LD) (segunda edición, 2015)

    Nefrologia, Vol. 36, Núm. 3, pp. e1-e52

  3. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab

    Biochemical Pharmacology, Vol. 122, pp. 33-41

2014

  1. Effect of Infliximab in oxidised serum albumin levels during experimental colitis

    Biomarkers, Vol. 19, Núm. 8, pp. 693-701

2013

  1. Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1

    Toxicology and Applied Pharmacology, Vol. 272, Núm. 3, pp. 568-578

2012

  1. Is the autophagy induced by thiopurines beneficial or deleterious?

    Current Drug Metabolism, Vol. 13, Núm. 9, pp. 1267-1276

2008

  1. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study

    World Journal of Gastroenterology, Vol. 14, Núm. 18, pp. 2851-2857

2007

  1. Thiopurine methyltransferase activity in Spain: A study of 14,545 patients

    Digestive Diseases and Sciences, Vol. 52, Núm. 5, pp. 1262-1269

2006

  1. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study

    Hepato-Gastroenterology, Vol. 53, Núm. 69, pp. 399-404

  2. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: Long-term follow-up study of 394 patients

    American Journal of Gastroenterology, Vol. 101, Núm. 12, pp. 2769-2776

2005

  1. Actividad de la tiopurina metiltransferasa en la enfermedad inflamatoria intestinal. Un estudio en 7.046 pacientes españoles

    Medicina Clinica, Vol. 125, Núm. 8, pp. 281-285

2004

  1. Effects of propofol and sevoflurane on the excitability of rat spinal motoneurones and nociceptive reflexes in vitro

    British Journal of Anaesthesia, Vol. 93, Núm. 3, pp. 422-427